Pharmacokinetics and Safety of Selumetinib Granule Formulation in Children With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas (SPRINKLE; phase I/II)

Journal of Clinical Oncology 2026 Open access

Read full text
Authors: Pablo Hernáiz Driever, Uwe R. Kordes, Ines B. Brecht, Veronica Saletti, Michael J. Fisher, Gail Doughton, Million Arefayene, Anna Rigazio, Nuria Lluch, Nereida Llorente, Scott J. Diede, Héctor Salvador
DOI: 10.1200/jco-25-01447
Cited by: 1
References: 19

Abstract

PURPOSE Neurofibromatosis type 1 (NF1)–associated plexiform neurofibroma (PN) can substantially affect quality of life. The capsule and granule formulations of selumetinib (ARRY-142886, AZD6244) are approved for pediatric patients with symptomatic, inoperable NF1-PN (age ≥1 to 3 years, region dependent). SPRINKLE (ClinicalTrials.gov identifier: NCT05309668 ) assessed pharmacokinetics (PK), safety, and palatability of the selumetinib granule formulation in children (age ≥1 to

Fields of Study & Subjects

Neurofibromatosis and Schwannoma Cases Sympathectomy and Hyperhidrosis Treatments Dupuytren's Contracture and Treatments

Publication details

Journal / source
Journal of Clinical Oncology
Publisher
American Society of Clinical Oncology (ASCO)
Volume
44
Issue
10
Pages
849–860
Publication date
27 January 2026
Language
EN